Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal

TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co said it has the financial capacity for fresh acquisitions to bolster its drug portfolio after agreeing on Monday to acquire cancer drug maker Ariad Pharmaceuticals in a $5.20 billion deal.

Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal
Read More


Bagikan Berita Ini